小分子抑制剂GSK3β:在多个系统中的治疗潜力和结构-活性关系
Jiale Wang1, Dan Wang1, Fanfei Liu1
1School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Tianjin, Jinghai District, Tianjin 301617, PR China.
Bioorganic chemistry
|October 9, 2025
概括
本综述详细介绍了针对各种疾病的26种小分子抑制剂,针对糖原合成酶激酶-3β (GSK3β). 它探讨了结构-活性关系和结合能力,以指导未来的药物开发.
科学领域:
- 生物化学和药理学 生物化学和药理学
- 药物发现和开发 药物发现和开发
背景情况:
- 蛋白激酶 (PK) 是调节细胞过程的重要酶,使它们成为药物开发的关键标.
- 蛋白激酶抑制剂是临床医学的一个重要领域,小分子抑制剂越来越突出.
- 糖原合成酶激酶-3β (GSK3β) 是一种代表性的PK,其抑制剂在临床上越来越多地使用.
研究的目的:
- 综合审查26种针对GSK3β的小分子抑制剂.
- 通过对九种主要系统性疾病的治疗应用对这些抑制剂进行分类.
- 探索GSK3β抑制剂的结构-活性关系和蛋白质结合能力.
主要方法:
- 26种GSK3β小分子抑制剂的文献综述和总结.
- 基于九种全身性疾病治疗应用的抑制剂的分类.
- 分子对接模拟以评估选择性抑制剂的蛋白质结合能力.
主要成果:
- 26种GSK3β小分子抑制剂及其治疗应用的概述.
- 对常见的GSK3β抑制剂化合物的结构-活性关系的分析.
- 鉴定具有强大的蛋白质结合能力的选择性抑制剂,许多在临床开发中.
结论:
- 本综述为针对各种疾病开发向的GSK3β小分子抑制剂提供了基础.
- 了解结构-活性关系和结合能力对于有效的药物设计至关重要.
- 建议未来的研究方向是为了推进用于临床应用的GSK3β抑制剂的开发.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Enzyme Inhibition
91.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.5K


